| Literature DB >> 29898673 |
Olga Theou1,2, Emma Squires3, Kayla Mallery3, Jacques S Lee4, Sherri Fay3, Judah Goldstein5, Joshua J Armstrong6, Kenneth Rockwood3,7.
Abstract
BACKGROUND: The ability of acute care providers to cope with the influx of frail older patients is increasingly stressed, and changes need to be made to improve care provided to older adults. Our purpose was to conduct a scoping review to map and synthesize the literature addressing frailty in the acute care setting in order to understand how to tackle this challenge. We also aimed to highlight the current gaps in frailty research.Entities:
Keywords: Acute care; Aging; Frail elderly; Frailty; Older adults; Scoping review
Mesh:
Year: 2018 PMID: 29898673 PMCID: PMC6000922 DOI: 10.1186/s12877-018-0823-2
Source DB: PubMed Journal: BMC Geriatr ISSN: 1471-2318 Impact factor: 3.921
Fig. 1Flow chart. 1The two reviewers agreed that these articles should be excluded but disagreed on the reason for exclusion. 2Additional articles were identified by manually searching the reference lists of systematic reviews focusing on frailty
Descriptive characteristics of the articles which included a frailty measure
| All | Geriatrics | Emergency Department | General Medicine | Cardiology | Orthopedics | Intensive Care Unit | Oncology | Surgery | Prehospital | General Medicine & Surgery | General Medicine & Geriatrics | Geriatrics & Oncology | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Articles n (%) | 204 (100) | 29 (14.2) | 29 (14.2) | 22 (10.8) | 20 (9.8) | 11 (5.4) | 9 (4.4) | 6 (2.9) | 5 (2.5) | 2 (1) | 18 (8.8) | 7 (3.4) | 2 (1) |
| Year n (%) | |||||||||||||
| 2011–2015 | 141 (69.1) | 14 (48.3) | 25 (86.2) | 19 (86.4) | 16 (80.0) | 11 (100.0) | 9 (100) | 3 (50.0) | 5 (100.0) | 2 (100.0) | 6 (33.3) | 2 (28.6) | 1 (50.0) |
| 2006–2010 | 39 (19.1) | 10 (34.5) | 3 (10.3) | 3 (13.6) | 2 (10.0) | 0 | 0 | 2 (33.3) | 0 | 0 | 5 (27.8) | 2 (28.6) | 0 |
| 2000–2005 | 24 (11.8) | 5 (17.2) | 1 (3.4) | 0 | 2 (10.0) | 0 | 0 | 1 (16.7) | 0 | 0 | 7 (38.9) | 3 (42.9) | 1 (50.0) |
| Language n (%) | |||||||||||||
| English | 200 (98.0) | 29 (100.0) | 27 (93.1) | 21 (95.5) | 20 (100.0) | 11 (100.0) | 9 (100.0) | 6 (100.0) | 4 (80.0) | 2 (100.0) | 18 (100.0) | 7 (100.0) | 2 (100.0) |
| Italian | 2 (1.0) | 0 | 1 (3.4) | 0 | 0 | 0 | 0 | 0 | 1 (20.0) | 0 | 0 | 0 | 0 |
| Portuguese | 2 (1.0) | 0 | 1 (3.4) | 1 (4.5) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Country n (%) | |||||||||||||
| United States | 55 (27.0) | 3 (10.3) | 11 (37.9) | 1 (4.5) | 6 (30.0) | 3 (27.3) | 2 (22.2) | 1 (16.7) | 3 (60.0) | 0 | 15 (83.3) | 0 | 0 |
| United Kingdom | 23 (11.3) | 4 (13.8) | 3 (10.3) | 5 (22.7) | 2 (10.0) | 2 (18.2) | 1 (11.1) | 0 | 0 | 0 | 1 (5.6) | 0 | 1 (50.0) |
| Canada | 18 (8.8) | 5 (17.2) | 2 (6.9) | 2 (9.1) | 1 (5.0) | 1 (9.1) | 4 (44.4) | 0 | 0 | 1 (50.0) | 0 | 0 | 0 |
| Australia/New Zealand | 16 (7.8) | 1 (3.4) | 1 (3.4) | 2 (9.1) | 1 (5.0) | 1 (9.1) | 1 (11.1) | 0 | 0 | 0 | 1 (5.6) | 0 | 1 (50.0) |
| Italy | 14 (6.9) | 3 (10.3) | 2 (6.9) | 3 (13.6) | 0 | 0 | 0 | 4 (66.7) | 1 (20.0) | 0 | 0 | 1 (14.3) | 0 |
| Belgium | 11 (5.4) | 6 (20.7) | 1 (3.4) | 2 (9.1) | 1 (5.0) | 1 (9.1) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Spain | 8 (3.9) | 2 (6.9) | 2 (6.9) | 0 | 3 (15.0) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Denmark | 8 (3.9) | 0 | 2 (6.9) | 2 (9.1) | 0 | 3 (27.3) | 0 | 0 | 0 | 0 | 0 | 1 (14.3) | 0 |
| Netherlands | 8 (3.9) | 1 (3.4) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (5.6) | 0 | 0 |
| Sweden | 6 (2.9) | 0 | 2 (6.9) | 0 | 0 | 0 | 0 | 0 | 0 | 1 (50.0) | 0 | 0 | 0 |
| Norway | 5 (2.5) | 0 | 0 | 1 (4.5) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 (57.1) | 0 |
| Other Europea | 15 (7.4) | 3 (10.3) | 1 (3.4) | 1 (4.5) | 2 (10.0) | 0 | 1 (11.1) | 1 (16.7) | 1 (20.0) | 0 | 0 | 0 | 0 |
| Otherb | 17 (8.3) | 1 (3.4) | 2 (6.9) | 3 (13.6) | 4 (20.0) | 0 | 0 | 0 | 0 | 0 | 0 | 1 (14.3) | 0 |
| Number of participants | |||||||||||||
| # of articles reporting | 201 | 28 | 29 | 21 | 19 | 11 | 9 | 6 | 5 | 2 | 18 | 7 | 2 |
| Range | 9–971,434 | 44–20,933 | 40–7532 | 34–3479 | 24–111,023 | 16–36,900 | 22–47,427 | 54–350 | 36–35,344 | 88–203 | 99–129,400 | 156–1568 | 37–111 |
| Median (IQR) | 206 (100.5–460) | 164 (99.3–490.3) | 161 (99.5–278) | 254 (118.5–562) | 309 (135–773) | 145 (47–284) | 421 (119–982) | 103 (69.8–180.5) | 41 (38.5–17,764) | N/A | 259.5 (397–1435.3) | 254 (254–254) | N/A |
| Mean age of participants | |||||||||||||
| # of articles reporting | 155 | 24 | 21 | 18 | 17 | 9 | 9 | 3 | 2 | 1 | 6 | 7 | 1 |
| Range | 47.1–91.6 | 66.4–86.7 | 75–86.8 | 65–86.5 | 53.2–91.6 | 47.1–87) | 60–84 | 62–73.1 | 72–76.9 | 82.2 | 60.4–77.3 | 60.8–82 | 74.3 |
| Median (IQR) | 78.9 (74–82.9) | 82.9 (79.9–84.1) | 78 (76.8–81.3) | 82.2 (77.9–84.1) | 76 (69.9–80.3) | 83.9 (77.3–86.3) | 76.9 (70–80.8) | 70.8 (N/A) | N/A | N/A | 74.1 (68.3–75.1) | 81.8 (72.8–81.8) | N/A |
| Percentage of females | |||||||||||||
| # of articles reporting | 187 | 27 | 27 | 20 | 19 | 11 | 9 | 6 | 4 | 1 | 15 | 7 | 1 |
| Range | 2–100 | 2.5–81.7 | 28–83 | 21.6–67.2 | 16.3–60 | 4.3–83 | 38.7–69.7 | 40.1–100 | 22.5–54.4 | 62.1 | 2–57 | 53–74.8 | 46 |
| Median (IQR) | 54 (43.5–63) | 63.7 (56–70) | 53 (41.7–56.4) | 60.4 (53.6–62.5) | 46 (39.3–50.7) | 75.4 (36.8–77.7) | 45 (42.5–53.1) | 45.5 (40.6–66.1) | 41.9 (24.5–54.1) | N/A | 2.8 (2.1–43.5) | 65 (54.6–65) | N/A |
We only stratified by disciplines that have been included in at least 2 articles
N/A not applicable, # number, IQR interquartile range
aAustria; Finland; France; Germany; Ireland; Poland; Slovenia; Switzerland
bBrazil; China; India; Israel; Japan; Mexico; Taiwan; Multiple Countries
Fig. 2Proportion of articles that measured frailty by study design. We only stratified by disciplines that have been included in at least 2 articles
Frailty charactseristics of included articles
| All | Geriatrics | Emergency Department | General Medicine | Cardiology | Orthopedics | Intensive Care Unit | Oncology | Surgery | Prehospital | General Medicine & Surgery | General Medicine & Geriatrics | Geriatrics & Oncology | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Articles n (%) | 240 (100) | 29 (12.1) | 29 (12.1) | 22 (9.2) | 20 (8.3) | 11 (4.6) | 9 (3.8) | 6 (3) | 5 (2.1) | 2 (0.8) | 18 (7.5) | 7 (2.9) | 2 (0.8) |
| When was frailty measured n (%) | |||||||||||||
| At admission | 94 (46.1) | 15 (51.7) | 18 (62.1) | 12 (54.5) | 6 (30.0) | 3 (27.3) | 5 (55.6) | 3 (50.0) | 3 (60.0) | 0 | 3 (16.7) | 6 (85.7) | 1 (50.0) |
| During hospitalization | 34 (16.7) | 9 (31.0) | 3 (10.3) | 5 (22.7) | 4 (20.0) | 2 (18.2) | 1 (11.1) | 2 (33.3) | 0 | 1 (50.0) | 3 (16.7) | 0 | 0 |
| At discharge | 10 (4.9) | 1 (3.4) | 1 (3.4) | 0 | 3 (15.0) | 0 | 1 (11.1) | 0 | 0 | 0 | 0 | 0 | 0 |
| Mixeda | 13 (6.4) | 1 (3.4) | 3 (10.3) | 2 (9.0) | 0 | 1 (9.1) | 0 | 1 (16.7) | 0 | 0 | 0 | 1 (14.3) | 0 |
| Chart/Database review | 27 (13.2) | 3 (10.3) | 3 (10.3) | 2 (9.1) | 6 (30.0) | 3 (27.3) | 2 (22.2) | 0 | 1 (20.0) | 1 (50.0) | 1 (5.6) | 0 | 0 |
| Not reported | 26 (12.7) | 0 | 1 (3.4) | 1 (4.5) | 1 (5.0) | 2 (18.2) | 0 | 0 | 1 (20.0) | 0 | 11 (61.1) | 0 | 1 (50.0) |
| Number of frailty measures used n (%) | |||||||||||||
| 1 | 185 (90.7) | 25 (86.2) | 27 (93.1) | 21 (95.5) | 16 (80.0) | 8 (72.7) | 8 (88.9) | 6 (100.0) | 4 (80.0) | 2 (100.0) | 18 (100.0) | 7 (100.0) | 2 (100.0) |
| 2 | 9 (4.4) | 3 (10.3) | 0 | 0 | 4 (20.0) | 0 | 1 (11.1) | 0 | 0 | 0 | 0 | 0 | 0 |
| 3 | 5 (2.5) | 0 | 2 (6.9) | 1 (4.5) | 0 | 2 (18.2) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 4 | 4 (2.0) | 1 (3.4) | 0 | 0 | 0 | 1 (9.1) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 6 | 1 (0.5) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (20.0) | 0 | 0 | 0 | 0 |
| Type of frailty measure n (%) | |||||||||||||
| Established frailty tools | 123 (51.3) | 17 (48.6) | 17 (51.5) | 17 (70.8) | 16 (66.7) | 6 (33.3) | 9 (90.0) | 3 (50.0) | 6 (60.0) | 1 (50.0) | 0 | 6 (85.7) | 1 (50.0) |
| Non-frailty toolsb | 57 (23.8) | 11 (31.4) | 13 (39.4) | 4 (16.7) | 3 (12.5) | 10 (55.6) | 0 | 1 (16.7) | 4 (40.0) | 0 | 1 (5.6) | 0 | 0 |
| Ad hoc measuresc | 56 (23.3) | 6 (17.1) | 3 (9.1) | 3 (12.5) | 4 (16.7) | 2 (11.1) | 1 (10.0) | 2 (33.3) | 0 | 1 (50.0) | 15 (83.3) | 1 (14.3) | 1 (50.0) |
| Clinical judgment | 4 (1.7) | 1 (2.9) | 0 | 0 | 1 (4.2) | 0 | 0 | 0 | 0 | 0 | 2 (11.1) | 0 | 0 |
| Frailty Measure used n (%) | |||||||||||||
| | |||||||||||||
| Clinical Frailty Scale | 28 (11.7) | 6 (17.1) | 4 (12.1) | 4 (16.7) | 3 (12.5) | 0 | 6 (60.0) | 0 | 0 | 0 | 0 | 0 | 0 |
| Frailty Phenotype | 28 (11.7) | 2 (5.7) | 4 (12.1) | 4 (16.7) | 6 (25.0) | 1 (5.6) | 2 (20.0) | 0 | 2 (20.0) | 0 | 0 | 1 (14.3) | 0 |
| Frailty Index | 28 (11.7) | 3 (8.6) | 7 (21.2) | 4 (16.7) | 1 (4.2) | 4 (22.2) | 1 (10.0) | 0 | 1 (10.0) | 1 (50.0) | 0 | 1 (14.3) | 0 |
| Edmonton Frailty Scale | 10 (4.2) | 0 | 2 (6.1) | 2 (8.3) | 2 (8.3) | 1 (5.6) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Winodgrad Index | 7 (2.9) | 0 | 0 | 1 (4.2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 (57.1) | 0 |
| Balducci criteria | 5 (2.1) | 0 | 0 | 0 | 0 | 0 | 0 | 3 (50.0) | 1 (10.0) | 0 | 0 | 0 | 1 (50.0) |
| Rockwood Geriatric Frailty Status | 5 (2.1) | 2 (5.7) | 0 | 0 | 1 (4.2) | 0 | 0 | 0 | 1 (10.0) | 0 | 0 | 0 | 0 |
| Study of Osteoporotic Fracture Index | 3 (1.3) | 2 (5.7) | 0 | 1 (4.2) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tilburg Frailty Indicator | 3 (1.3) | 0 | 0 | 1 (4.2) | 2 (8.3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| FRAIL scale | 2 (0.8) | 1 (2.9) | 0 | 0 | 1 (4.2) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Groningen Frailty Indicator | 2 (0.8) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (10.0) | 0 | 0 | 0 | 0 |
| Other established toolsd | 2 (0.8) | 1 (2.9) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | |||||||||||||
| Identification of Seniors at Risk | 12 (5.0) | 4 (11.4) | 3 (9.1) | 2 (8.3) | 1 (4.2) | 1 (5.6) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Vulnerable Elders Survey | 5 (2.1) | 0 | 3 (9.1) | 0 | 0 | 0 | 0 | 0 | 1 (10.0) | 0 | 0 | 0 | 0 |
| Grip strength | 4 (1.7) | 2 (5.7) | 0 | 0 | 0 | 1 (5.6) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Barthel Index | 2 (0.8) | 0 | 2 (6.1) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Life Space Assessment | 2 (0.8) | 0 | 2 (6.1) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Multidimensional Prognosis Index | 2 (0.8) | 2 (5.7) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short Physical Performance Battery | 2 (0.8) | 1 (2.9) | 0 | 0 | 0 | 0 | 0 | 1 (16.7) | 0 | 0 | 0 | 0 | 0 |
| Other non-frailty toolse | 28 (11.7) | 2 (5.7) | 3 (9.1) | 2 (9.1) | 2 (8.3) | 8 (44.4) | 0 | 0 | 3 (30.0) | 0 | 1 (5.6) | 0 | 0 |
| | |||||||||||||
| GEM criteriaf | 12 (5.0) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 (66.7) | 0 | 0 |
| Other ad hoc measures | 44 (18.3) | 6 (17.1) | 3 (9.1) | 3 (12.5) | 4 (16.7) | 2 (11.1) | 1 (10.0) | 2 (33.3) | 0 | 1 (50.0) | 3 (16.7) | 1 (14.3) | 1 (50.0) |
| | 4 (1.7) | 1 (2.9) | 0 | 0 | 1 (4.2) | 0 | 0 | 0 | 0 | 0 | 2 (11.1) | 0 | 0 |
| Purpose of frailty use n (%) | |||||||||||||
| Risk stratificationg | 89 (43.6) | 12 (41.4) | 15 (51.7) | 10 (45.5) | 11 (55.0) | 8 (72.7) | 8 (88.9) | 2 (33.3) | 2 (40.0) | 1 (50.0) | 3 (16.7) | 2 (28.6) | 0 |
| Inclusion/Exclusion criterion | 41 (20.1) | 4 (13.8) | 3 (10.3) | 4 (18.2) | 1 (5.0) | 0 | 0 | 0 | 1 (20.0) | 1 (50.0) | 13 (72.2) | 5 (71.4) | 0 |
| Outcome measure | 4 (2.0) | 1 (3.4) | 1 (3.4) | 0 | 1 (5.0) | 1 (9.1) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Mixedh | 3 (1.5) | 0 | 0 | 2 (9.0) | 0 | 0 | 0 | 1 (16.7) | 0 | 0 | 0 | 0 | 0 |
| Only descriptivei | 67 (32.8) | 12 (41.4) | 10 (34.5) | 6 (27.3) | 7 (35.0) | 2 (18.2) | 1 (11.1) | 3 (50.0) | 2 (40.0) | 0 | 2 (11.1) | 0 | 2 (100.0) |
| Prevalence of frailty (%) | |||||||||||||
| # of articles reporting | 122 | 17 | 13 | 12 | 17 | 5 | 8 | 5 | 7 | 0 | 4 | 2 | 1 |
| Range | 1.1–100 | 1.1–90.0 | 6.9–78.0 | 23.0–77.9 | 4.7–77.8 | 11.4–89.4 | 13.7–100 | 19.1–96.7 | 29.3–79.9 | N/A | 30.3–91.0 | 41.4–59.0 | 26.0 |
| Median (IQR) | 48.5 (32.0–69.5) | 43.3 (26.9–70.7) | 46.7 (34.2–70.2) | 51.3 (34.8–55.2) | 35.5 (28.7–69) | 68.5 (31.2–89.4) | 33.5 (25.3–47.0 | 41.4 (26.7–81.0) | 54.3 (50.0–70.7) | N/A | 45.3 (32.2–81.4) | N/A | N/A |
| Adverse outcomes predicted by frailty [n predicted/total measured (% predictive)]j | |||||||||||||
| | 169/228 (74.1) | 23/30 (69.7) | 25/32 (78.1) | 18/22 (81.8) | 15/19 (78.9) | 11/16 (68.8) | 22/33 (66.7) | 4/8 (50) | 11/14 (78.6) | 1/1 (100) | 4/4 (100) | 2/3 (66.7) | 0 |
| | 58/69 (84.1) | 13/14 (92.9) | 6/7 (85.7) | 4/4 (100.0) | 7/10 (70.0) | 4/5 (80.0) | 6/8 (75.0) | 1/2 (50.0) | 6/7 (85.7) | 1/1 (100.0) | 0 | 0 | 0 |
| | 24/33 (72.7) | 3/5 (60.0) | 4/5 (80.0) | 4/7 (57.1) | 2/2 (100.0) | 3/3 (100.0) | 3/6 (50.0) | 0 | 0 | 0 | 1/1 (100.0) | 2/2 (100.0) | 0 |
| | 20/29 (69.0) | 0 | 2/2 (100.0) | 0 | 2/2 (100.0) | 1/4 (25.0) | 1/3 (33.3) | 1/2 (50.0) | 5/7 (71.4) | 0 | 1/1 (100.0) | 0 | 0 |
| | 27/29 (93.1) | 1/1 (100.0) | 6/6 (100.0) | 7/7 (100.0) | 1/1 (100.0) | 1/1 (100.0) | 5/7 (71.4) | 1/1 (100.0) | 0 | 0 | 0 | 0 | 0 |
| | 9/18 (50.0) | 3/4 (75.0) | 3/5 (60.0) | 0/1 (0) | 1/1 (100.0) | 0 | 0/1 (0) | 0 | 0 | 0 | 1/1 (100.0) | 0 | 0 |
| | 8/8 (66.7) | 2/2 (100.0) | 2/4 (50.0) | 1/1 (100.0) | 0 | 0 | 3/3 (100.0) | 0 | 0 | 0 | 0 | 0/1 (0) | 0 |
| | 8/8 (66.7) | 1/1 (100.0) | 0/1 (0) | 0 | 2/3 (66.7) | 0 | 2/3 (66.7) | 0/1 (0) | 0 | 0 | 1/1 (100.0) | 0 | 0 |
| | 3/7 (42.9) | 0/4 (0) | 1/1 (100.0) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | 1/4 (25.0) | 0/2 (0) | 0 | 1/1 (100.0) | 0 | 0/1 (0) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | 4/4 (100.0) | 0 | 0 | 1/1 (100.0) | 0 | 0 | 0 | 1/1 (100.0) | 0 | 0 | 0 | 0 | 0 |
| | 0/3 (0) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | 2/2 (100.0) | 0 | 0 | 0 | 0 | 1/1 (100.0) | 1/1 (100.0) | 0 | 0 | 0 | 0 | 0 | 0 |
| | 5/6 (83.3) | 0 | 1/2 (50.0) | 0 | 0 | 1/1 (100.0) | 1/1 (100.0) | 0 | 0 | 0 | 0 | 0 | 0 |
We only stratified by disciplines that have been included in at least 2 articles
N/A not applicable, # number, IQR interquartile range
aMultiple testings for each patient or different testing times for subgroup of patients
bTools that were not developed specifically for measuring frailty
cOperationalized definitions of frailty (for example, ≥65 years of age plus 3 comorbidities)
dClinical Global Impression of Change in Physical Frailty; Geriatrician Clinical Impression of Frailty
eNon-frailty tools that were used only once
fThe Geriatric Evaluation and Management (GEM) drug study criterion was meeting at least 2 of the following 10 criteria: dependence in at least one activity of daily living, stroke within 3 months, previous falls, difficulty ambulating, malnutrition, dementia, depression, unplanned admission in the last 3 months, prolonged bed rest, or incontinence
gArticles that examined the association of a frailty measure with a longitudinal adverse outcome
hInclusion/Exclusions criterion and outcome measure; risk stratification and outcome measure
iArticles which only used frailty as a descriptive characteristic. For example, if an article used frailty both as an inclusion/exclusion criterion and a descriptive characteristic, it was only categorized as inclusion/exclusion criterion in our review
jMore than one outcome can be examined within each article
kFor example, change in anticoagulant use
lFor example, antibody levels
mAdverse outcomes that were examined only once
Ranking of the most commonly used measures by discipline
| Ranked | All | Geriatrics ( | Emergency Department ( | General Medicine ( | Cardiology ( | Orthopedics ( | Intensive Care Unit ( | Oncology ( | Surgery ( | Prehospital ( | General Medicine & Surgery ( | General Medicine & Geriatrics ( | Geriatrics & Oncology ( |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Clinical Frailty Scale (12%), Frailty Phenotype (12%), Frailty Index (12%) | Clinical Frailty Scale (17%) | Frailty Index (21%) | Clinical Frailty Scale (17%), Frailty Phenotype (17%), Frailty Index (17%) | Frailty Phenotype (25%) | Frailty Index (22%) | Clinical Frailty Scale (60%) | Balducci Criteria (50%) | Frailty Phenotype (20%) | Frailty Index (50%) | GEM Criteriaa (67%) | Winograd Index (57%) | Balducci Criteria (50%) |
| 2 | Identification of Seniors at Risk (11%) | Clinical Frailty Scale (12%), Frailty Phenotype (12%) | Clinical Frailty Scale (13%) | Frailty Phenotype (6%), Edmonton Frailty Scale (6%), Identification of Seniors at Risk (6%), Grip Strength (6%) | Frailty Phenotype (20%) | Short Physical Performance Battery (17%) | Frailty Index (10%), Groningen (10%), Balducci Criteria (10%), Rockwood Geriatric Frailty Status (10%), Vulnerable Elders Survey (10%) | N/A | N/A | Frailty Index (14%), Frailty Phenotype (14%) | N/A | ||
| 3 | Frailty Index (9%) | Edmonton Frailty Scale (8%), Tilburg Frailty Indicator (8%) | Frailty Index (10%) | N/A | |||||||||
| 4 | Identification of Seniors at Risk (5%), GEM Criteriaa (5%) | Frailty Phenotype (6%), Study of Osteoporotic Fracture Index (6%), Rockwood Geriatric Frailty Status (6%), Multidimensional Prognosis Index (6%), Grip Strength (6%) | Identification of Seniors at Risk (9%), Vulnerable Elders Survey (9%) | Edmonton Frailty Scale (8%), Identification of Seniors at Risk (8%) | N/A | N/A | |||||||
| 5 | Frailty Index (4%), Rockwood Geriatric Frailty Status (4%), FRAIL scale (4%), Identification of Seniors At Risk (4%) |
We only stratified by disciplines that have been included in at least 2 articles
N/A not applicable
aThe Geriatric Evaluation and Management (GEM) drug study criterion was meeting at least 2 of the following 10 criteria: dependence in at least one activity of daily living, stroke within 3 months, previous falls, difficulty ambulating, malnutrition, dementia, depression, unplanned admission in the last 3 months, prolonged bed rest, or incontinence
Fig. 3Proportion of articles based on the reason frailty measures were used in the articles. Stratified by (a). Year (b). Study design. 1Articles which only used frailty as a descriptive characteristic. For example, if an article used frailty both as an inclusion/exclusion criterion and a descriptive characteristic, it was only categorized as inclusion/exclusion criterion in our review. 2Inclusion/Exclusions criterion and outcome measure; risk stratification and outcome measure. 3Articles that examined the association of a frailty tool with a longitudinal adverse outcome
Fig. 4Number of times that the association of a frailty tool with a longitudinal outcome was examined. 1 For example, change in anticoagulant use. 2 For example, antibody levels. 3 Adverse outcomes that were examined only once
Fig. 5Proportion of articles demonstrating the association of frailty with longitudinal adverse outcomes stratified by frailty measure. We only presented the established frailty tools whose association with outcomes were examined at least 5 times